Stocks · News reference

HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral

Aug 11, 2026, 12:31 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 11, 2026, 12:31 PM
Checked: Aug 11, 2026, 12:31 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 29, 2026, 9:07 PMBenzinga Newsdesk
Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement
HRTX
SEC EDGARSep 29, 2026, 9:00 PMSEC EDGAR
8-K filing — HERON THERAPEUTICS, INC. /DE/ (HRTX)
Filed: 2026-09-29 AccNo: 0001193125-26-407728 Size: 198 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
HRTX
BenzingaAug 10, 2026, 6:00 PMBenzinga Newsdesk
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
HRTX